The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection

BACKGROUND: Tuberculosis (TB) causes a major burden on global health with long and cumbersome TB treatment regimens. Host-directed immune modulating therapies have been suggested as adjunctive treatment to TB antibiotics. Upregulated cyclooxygenase-2 (COX-2)-prostaglandin E2 (PGE2) signaling pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonby, Kristian, Wergeland, Ida, Lieske, Nora V., Kvale, Dag, Tasken, Kjetil, Dyrhol-Riise, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078976/
https://www.ncbi.nlm.nih.gov/pubmed/27776487
http://dx.doi.org/10.1186/s12879-016-1938-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078976/
https://www.ncbi.nlm.nih.gov/pubmed/27776487
http://dx.doi.org/10.1186/s12879-016-1938-8

Ejemplares similares